Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

LONDON, December 12, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational "Zamore Design Rule" patent families. Following a review requested by an anonymous third party during 2010, the USPTO has concluded that the reissued claims are patentable and has issued Notices of Intent to Issue Reexamination Certificates. The prior art cited in the reexaminations was unsuccessful in invalidating the patents.

The four patents (US 7,459,547, US 7,732,593, US 7,772,203 and US 7,750,144) form part of the foundational "Zamore Design Rule" patent families that disclose various efficacy-enhancing methods and structural elements for RNAi therapeutics. Silence has exclusively licensed three "Zamore Design Rule" patent families in their entirety for applications in the human healthcare field from the University of Massachusetts Medical School. The three patent families generally disclose methods of enhancing the silencing activity of RNAi agents through certain structural modifications. The claims associated with the reexaminations include coverage for methods of enhancing silencing of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin RNA (shRNA) molecules.

Thomas Christély, Chief Executive Officer of Silence Therapeutics, said: "We are very pleased that the USPTO has reissued these four patents. This outcome sends a clear message regarding the strength of Silence's intellectual property. We believe that there is significant value in the Zamore technology as a fundament
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... VANCOUVER , July 29, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company, is pleased to announce ... dermal injector (RCI-02) have been locked.  Prototypes for ... to prepare for an application for CE mark ... Europe in 2016. (Photo: ...
(Date:7/29/2015)... ... ... Finding gooey or crusty material in the corner of your eyes as ... of terms in popular use to describe it, ophthalmologists call it “gound” or “rheum”. ... cells, skin cells and dust, but until now there has been virtually no research ...
(Date:7/29/2015)... ... 29, 2015 , ... Available in select spas and ... nighttime-specific product that targets fat cells for extreme contouring action. During sleep key ... cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down fat ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Industries’ (BI) advanced cell culture products, announces the availability of BI’s line of ... by Biological Industries, these stem cell differentiation media offer a complete system for ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3
... Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading ... and stem cell research systems, today announced positive ... These validation results were presented today by ... University of Pittsburgh School of Medicine as ...
... Calif., Feb. 25 Cord Blood America, Inc. ... stem cell preservation company ( http://www.cordblood-america.com ) focused ... cells to families nationwide and internationally, today announced ... restructure its current outstanding debt."The restructuring is a ...
... development of CureDM,s HIP2B peptide targeted for the treatment of type 1 ... ... 2009 -- Calvert Research, LLC (a Calvert Holdings, Inc. ... CureDM to continue the preclinical development of CureDM,s HIP2B peptide. Calvert ...
Cached Biology Technology:Data on WaferGen's SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference 2Data on WaferGen's SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference 3Data on WaferGen's SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference 4Data on WaferGen's SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference 5Cord Blood America Restructures Debt; Projects to be Cash Flow Positive 2Calvert Research and CureDM Sign Collaborative Agreement 2Calvert Research and CureDM Sign Collaborative Agreement 3
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading ... for its second quarter ended June 30, 2015.  ... million, a decrease of 33% compared to $6.8 million in ... quarter of 2015 was $0.3 million, or $0.01 per diluted ... share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in finger-based biometric identification solutions, today announced that it has ... media, industry analyst, investor relations and other communications initiatives. , ... ... , ...
... are the cells responsible for immune surveillance in the ... to tissue damage and infection. An international team under ... now shown that these cells may actually make a ... Alzheimer,s disease. About 1.2 million people are thought to ...
... more than 500 million years ago has provided new insight ... London. Professor Maurice Elphick, from Queen Mary,s School of ... explain a rare form of the disease that causes sufferers ... reported in the journal Gene , Professor Elphick has ...
Cached Biology News:BIO-key(R) International Taps JMR Worldwide for PR, IR and Strategic Communications 2BIO-key(R) International Taps JMR Worldwide for PR, IR and Strategic Communications 3BIO-key(R) International Taps JMR Worldwide for PR, IR and Strategic Communications 4BIO-key(R) International Taps JMR Worldwide for PR, IR and Strategic Communications 5Dangerous custodians 2
... Agencourt offers SNP loci identification through ... automated assay design, intensive assay validation/optimization, ... of Corriell or customer-supplied samples and ... service provides for rapid and highly ...
... Tissue Extract Protein Array Kit is designed ... extracts. The expression of a protein in ... specific antibody. When the antibody binds the ... sensitive chemiluminescent or fluorescent signal created by ...
... statistics and statistical interpretation to researchers, ... As an accepted organizational standard for ... for novice users and includes the ... offers a powerful JMP Scripting Language ...
... StabilGuard Choice Microsphere/Microarray Stabilizer is a ... Plus Stabilizer. This product is an ... a PBS buffer (phosphate buffered saline), pH ... a combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: